Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/81609
Title: Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China : a protocol for a systematic review and network meta-analysis
Authors: Hua, Z
Zhai, FT
Tian, J
Gao, CF 
Xu, P
Zhang, F
Liu, SJ
Dong, K
Du, XF
Zhang, Z
Yang, G
Keywords: Angina, Unstable
Network meta-analysis
Protocol
Traditional Chinese Medicine
Issue Date: 2019
Publisher: BMJ Publishing Group Ltd
Source: BMJ open, 2019, v. 9, no. 9, e026136 How to cite?
Journal: Micromachines 
Abstract: Introduction Achieving efficacious and safe treatments for unstable angina pectoris (UAP) is still a challenging clinical problem. The availability of different oral Chinese patent medicines frequently poses a practical challenge to clinicians, namely, which one to choose as first-line regimen for treatment. This study aims to examine the comparative effectiveness and safety of oral Chinese patent medicines for UAP on the national essential drugs list of China.
Methods and analysis We will conduct a network meta-analysis (NMA) of all randomised controlled trials to evaluate the use of oral Chinese patent medicines as adjuvant for the treatment of UAP. We will explore eight electronic databases from their inception to June 2018 and search for grey literature. Primary outcomes include mortality and the cardiovascular events. Secondary outcomes include: (1) symptom improvement; (2) ECG improvement; (3) frequency of acute angina attack; (4) duration of angina; (5) adverse effects. Two independent authors will screen titles and abstracts, review full texts, extract data, assess the risk of bias using the Cochrane risk of bias tool and assess the quality of evidence and strength of the recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). If adequate data are available, NMA will be performed with Bayesian analysis methods.
Ethics and dissemination The NMA will help us to reduce the uncertainty of interventions and help clinicians to make optimal and more accurate therapeutic decisions for adults with UAP. Therefore, we will publish the findings of this study in a peer-reviewed journal. No ethics approval is necessary for this study based on the nature of its design. Trial registration number CRD42018092822.
URI: http://hdl.handle.net/10397/81609
ISSN: 2044-6055
EISSN: 2044-6055
DOI: 10.1136/bmjopen-2018-026136
Rights: © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
The following publication Hua Z, Zhai F, Tian J, et alEffectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysisBMJ Open 2019;9:e026136, is available at https://doi.org/10.1136/bmjopen-2018-026136
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Hua_Effectiveness_safety_oral.pdf1.38 MBAdobe PDFView/Open
Access
View full-text via PolyU eLinks SFX Query
Show full item record
PIRA download icon_1.1View/Download Contents

Page view(s)

8
Citations as of Feb 19, 2020

Download(s)

6
Citations as of Feb 19, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.